Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
about
Melanoma: from melanocyte to genetic alterations and clinical optionsResistant mechanisms to BRAF inhibitors in melanomaThe evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyOther targeted drugs in melanomaTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done YetEmerging targeted therapies for melanoma treatment (review)Pathways and therapeutic targets in melanomaActivated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsCIViC databaseA novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionWhole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy responseBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients.Resistance to Raf inhibition in cancer.Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials.Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.Evaluating melanoma drug response and therapeutic escape with quantitative proteomicsActivated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation.Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challengesNovel anti-melanoma treatment: focus on immunotherapy.Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutationsCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorA molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.Genotyping of cutaneous melanoma.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatmentOvercoming resistance to BRAF inhibition in BRAF-mutated metastatic melanomaBeyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaROCK1 is a potential combinatorial drug target for BRAF mutant melanomaCombining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
P2860
Q21284811-975BF13B-CBDC-43FF-9E2C-BE3D169F55A0Q26739717-8033129E-E4B7-479C-8640-122049D009FDQ26744335-6AF2D46A-01BD-4FAD-829A-EDD3DF3F67BEQ26771192-F8439A45-A924-4A12-A593-36DA6EE80D00Q26775594-304BDB4E-9461-4970-BB95-16CEFDEE3C31Q26782222-2765C062-90CD-4D29-A07F-6FDBBD211792Q26799864-3EEA5F64-69B9-46D3-AFAC-A4EF06524FFCQ26829997-4A1FC23D-3333-4299-AE47-5F98CFA07430Q26865736-D20AE8B0-1D3C-4BAD-8CBB-831F1AFEA692Q27027458-CF090FB4-8B4D-4EFE-9545-99F4AD373CD0Q27612411-777C024C-8351-40BD-8A56-7E959A9529F0Q27852692-1D7936DB-A993-4CF6-88F6-250CB808F7B8Q27852827-32A04546-3E14-40AA-957B-D885FC082C83Q27853105-FF936937-7EF7-4DA4-8922-3C769FA3F9A7Q30277902-659EE223-918E-486C-8700-F7D84BDAC7B9Q30384301-C7986D49-6FF9-4B8C-B35A-D8505CD6EF4BQ30458424-AADDB396-2E19-4D90-BD84-114587755D6CQ33566681-3ACEAAF4-1C97-4AEA-8548-5307091BE37EQ33650820-6DCC1445-A5E3-4131-9150-A824FA40197AQ33651779-8CC09E80-F6AB-4104-A1CE-82C896EC5FE0Q33762080-A326EC93-241E-4233-B1DC-E15838BDB469Q33830911-1959D310-D9CE-4403-8CC5-D80A44029D40Q33850665-C7B6F92C-A79C-4050-99DA-156DBBE351FCQ33884726-C43FFBE3-A12A-45C5-8C27-DF336249E12EQ33935045-0046D6F2-9C25-4773-A74E-0FC2E8661CB8Q34001762-1C7EE8F5-4CC8-4865-852E-6D8679FC1C0CQ34159519-6D1ECEEC-8A7C-4244-8B18-1B5F5FA460DFQ34185078-1D61B48C-BF15-4249-9A0F-513BBB2FAE55Q34309404-E102D0AD-BF9D-43FD-A308-D2CB1D4CC395Q34438555-01574BDA-CB68-402F-B063-EAF584E04352Q34484174-9F238FA2-BD29-4981-9B6F-620627581E65Q34582560-1E29606F-F875-4D03-B194-D05A5C980C34Q34667738-0FA59487-B6EC-4642-B360-640DBED653B2Q34667825-BAC7308C-7523-416C-9F24-AB94B42267FBQ34677194-F3387C66-81E2-42E2-8975-469E9B306698Q34736597-E646FF40-D2FA-4A04-96E4-1CE0FB495E5EQ34786402-82A29937-A38A-4FD8-AEE3-90E8D73D4DB6Q34898560-455A4B78-5EA4-47FE-B488-B738F45EED99Q34990555-A81253A3-8824-4FDA-AB06-6EB0177D206EQ35063621-935C952F-B832-4F07-B7F3-DB8DA4177F45
P2860
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacodynamic effects and me ...... ents with metastatic melanoma.
@ast
Pharmacodynamic effects and me ...... ents with metastatic melanoma.
@en
Pharmacodynamic effects and me ...... ents with metastatic melanoma.
@nl
type
label
Pharmacodynamic effects and me ...... ents with metastatic melanoma.
@ast
Pharmacodynamic effects and me ...... ents with metastatic melanoma.
@en
Pharmacodynamic effects and me ...... ents with metastatic melanoma.
@nl
prefLabel
Pharmacodynamic effects and me ...... ents with metastatic melanoma.
@ast
Pharmacodynamic effects and me ...... ents with metastatic melanoma.
@en
Pharmacodynamic effects and me ...... ents with metastatic melanoma.
@nl
P2093
P50
P3181
P356
P1476
Pharmacodynamic effects and me ...... ents with metastatic melanoma.
@en
P2093
Andrew K Joe
Anna C Pavlick
Astrid Koehler
Donald Lawrence
Houston N Gilbert
Jeffrey A Sosman
Jeffrey S Weber
Karl D Lewis
Kerstin Trunzer
Kevin B Kim
P304
P3181
P356
10.1200/JCO.2012.44.7888
P407
P50
P577
2013-05-10T00:00:00Z